Adnan Kastrati
A5015669756- Coronary Interventions and Diagnostics
- Acute Myocardial Infarction Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cardiac Imaging and Diagnostics
- Cardiac Valve Diseases and Treatments
- Atrial Fibrillation Management and Outcomes
- Cerebrovascular and Carotid Artery Diseases
- Venous Thromboembolism Diagnosis and Management
- Peripheral Artery Disease Management
- Lipoproteins and Cardiovascular Health
- Cardiovascular Function and Risk Factors
- Aortic aneurysm repair treatments
- Infective Endocarditis Diagnosis and Management
- Vascular Procedures and Complications
- Cardiac, Anesthesia and Surgical Outcomes
- Heart Failure Treatment and Management
- Atherosclerosis and Cardiovascular Diseases
- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Cardiac and Coronary Surgery Techniques
- Cardiac Arrest and Resuscitation
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cardiac pacing and defibrillation studies
- Diabetes Treatment and Management
- Aortic Disease and Treatment Approaches
Deutsches Herzzentrum München
2016-2025
German Centre for Cardiovascular Research
2016-2025
Technical University of Munich
2016-2025
Deutsches Herzzentrum der Charité
2016-2025
Bavarian Research Alliance
2013-2023
Autonomous University of Aguascalientes
2023
Icahn School of Medicine at Mount Sinai
2016-2022
Novo Nordisk (Finland)
2022
Amgen (United States)
2022
Cardinal Health (Australia)
2022
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force European Society Cardiology (ESC)
ACE angiotensin-converting enzyme ACS acute coronary syndrome ADP adenosine diphosphate AF atrial fibrillation AMI myocardial infarction AV atrioventricular AIDA-4 Abciximab Intracoronary vs
Kristian Thygesen∗ (Denmark) Joseph S. Alpert∗ (USA) Allan Jaffe (USA) Bernard R. Chaitman (USA) Jeroen J. Bax (The Netherlands) David A. Morrow (USA) Harvey D. White∗ (New Zealand) Hans Mickley (Denmark) Filippo Crea (Italy) Frans Van de Werf (Belgium) Chiara Bucciarelli-Ducci (
A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895
The ESC/EACTS Guidelines represent the views of ESC and EACTS were produced after careful consideration scientific medical knowledge evidence available at time their dating.The are not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals encouraged take ESC/ fully into account when exercising...
The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical...
The ESC Guidelines represent the views of and were arrived at after careful consideration available evidence time they written.Health professionals are encouraged to take them fully into account when exercising their clinical judgement.The guidelines do not, however, override individual responsibility health make appropriate decisions in circumstances patients, consultation with that patient, where necessary patient's guardian or carer.It is also professional's verify rules regulations...
The clinical benefit of coronary-artery stenting performed in conjunction with coronary angioplasty is limited by the risk thrombotic occlusion stent as well hemorrhagic and vascular complications intensive anticoagulation. We compared antiplatelet therapy conventional anticoagulant respect to outcomes 30 days after stenting.
Cardiac computed tomography (CT) angiography (CCTA) has emerged as a useful diagnostic imaging modality in the assessment of coronary artery disease. However, potential risks due to exposure ionizing radiation associated with CCTA have raised concerns.To estimate dose routine clinical practice well association currently available strategies reduction and identify independent factors contributing dose.A cross-sectional, international, multicenter, observational study (50 sites: 21 university...
Increased thrombogenicity and smooth muscle cell proliferative response induced by the metal struts compromise advantages of coronary stenting. The objective this randomized, multicenter study was to assess whether a reduced strut thickness stents is associated with improved follow-up angiographic clinical results.A total 651 patients lesions situated in native vessels >2.8 mm diameter were randomly assigned receive 1 2 commercially available comparable design but different thickness: 326...
Monotherapy with a P2Y12 inhibitor after minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk bleeding percutaneous coronary intervention (PCI).
No specifically designed studies have addressed the role of glycoprotein IIb/IIIa inhibitor abciximab in patients with non-ST-segment elevation acute coronary syndromes (ACS) undergoing percutaneous intervention (PCI) after pretreatment 600 mg clopidogrel.To assess whether is associated clinical benefit high-risk ACS PCI clopidogrel.International, multicenter, randomized, double-blind, placebo-controlled study conducted from March 2003 through December 2005, enrolling 2022 (mean age, 66...
Multislice computed tomography angiography (CTA) is a promising technology for imaging patients with suspected coronary artery disease. Compared 16-slice CTA, the improved spatial and temporal resolution of 64-slice CTA (0.6- versus 1.0-mm slice thickness 330- 420-ms gantry rotation time) associated an increase in radiation dose. The objective this retrospective investigation was to compare estimated dose received during 16- daily practice investigate impact different scan protocols on image...
The relative merits of ticagrelor as compared with prasugrel in patients acute coronary syndromes for whom invasive evaluation is planned are uncertain.In this multicenter, randomized, open-label trial, we randomly assigned who presented and was to receive either or prasugrel. primary end point the composite death, myocardial infarction, stroke at 1 year. A major secondary (the safety point) bleeding.A total 4018 underwent randomization. end-point event occurred 184 2012 (9.3%) group 137...